Mirna Therapeutics Selected For $10.3M Commercialization Award

Austin-based Mirna Therapeutics, a biotechnology spinoff of Asuragen focused on miRNA–directed therapeutics for the treatment of cancer, said today that it has received notice of a $10.3M award from the State of Texas. The firm said the commercialization award was from the Cancer Prevention and Research Institute of Texas. The firm said the award is one of three being recommended for the inaugural commercialization awards by the CPRIT. The firm said the funding is still subject to due diligence and contract negotiations.